Xeris Pharmaceuticals Inc. (XERS) and Sutro Biopharma Inc. (NASDAQ:STRO) Comparing side by side

Both Xeris Pharmaceuticals Inc. (NASDAQ:XERS) and Sutro Biopharma Inc. (NASDAQ:STRO) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Xeris Pharmaceuticals Inc. 2.46M 106.65 60.08M -2.41 0.00
Sutro Biopharma Inc. 38.42M 7.02 35.32M -2.21 0.00

Demonstrates Xeris Pharmaceuticals Inc. and Sutro Biopharma Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Xeris Pharmaceuticals Inc. -2,442.28% 0% 0%
Sutro Biopharma Inc. -91.93% 0% 0%

Liquidity

16.5 and 16.5 are the respective Current Ratio and a Quick Ratio of Xeris Pharmaceuticals Inc. Its rival Sutro Biopharma Inc.’s Current and Quick Ratios are 3.5 and 3.5 respectively. Xeris Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Sutro Biopharma Inc.

Institutional & Insider Ownership

Roughly 48.6% of Xeris Pharmaceuticals Inc. shares are owned by institutional investors while 75.3% of Sutro Biopharma Inc. are owned by institutional investors. Insiders owned 2.4% of Xeris Pharmaceuticals Inc. shares. Comparatively, Sutro Biopharma Inc. has 8.5% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Xeris Pharmaceuticals Inc. 3.75% -24.35% -47.89% -59.92% 0% -38.24%
Sutro Biopharma Inc. -9.77% -14.46% -12.05% 0% 0% 0.33%

For the past year Xeris Pharmaceuticals Inc. had bearish trend while Sutro Biopharma Inc. had bullish trend.

Summary

Sutro Biopharma Inc. beats Xeris Pharmaceuticals Inc. on 6 of the 8 factors.

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company's preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.